Description
Ilumya (tildrakizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It is a humanized IgG1κ monoclonal antibody that selectively targets interleukin-23 (IL-23), a cytokine involved in the inflammatory response underlying psoriasis. By blocking IL-23, Ilumya reduces inflammation and skin cell proliferation.
Uses:
Ilumya is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Storage Conditions:
Ilumya should be stored in a refrigerator at 36°F to 46°F (2°C to 8°C) in its original packaging. It should not be frozen or shaken. Once removed from the refrigerator, it can be stored at room temperature for up to 24 hours.
Mechanism of Action:
Ilumya is a humanized IgG1κ monoclonal antibody that selectively targets IL-23, a cytokine involved in the inflammatory response underlying psoriasis. By blocking IL-23, Ilumya reduces inflammation and skin cell proliferation.
HOW TO USE:
Ilumya is administered by a healthcare provider as a subcutaneous injection every 12 weeks. Patients should receive the injection from a trained healthcare professional in a medical setting.
Precautions:
• Patients should inform their healthcare provider if they have a history of infections or if they develop signs of an infection while taking Ilumya.
• Ilumya may increase the risk of serious infections, including tuberculosis and invasive fungal infections.
• Patients should inform their healthcare provider if they are pregnant or planning to become pregnant.
Drug Interactions:
• Ilumya may interact with other medications, including immunosuppressive agents, which can increase the risk of infections.
• Patients should inform their healthcare provider of all the medications they are taking before starting Ilumya.
Contraindications:
• Ilumya should not be used in patients with a previous hypersensitivity reaction to the medication or its components.
• It is not recommended for the treatment of patients with clinically significant active infections.
Overdose:
There is limited information on the overdose of Ilumya. However, patients who take a higher-than-prescribed dosage of Ilumya should seek medical attention.
Adverse Reactions:
The most common adverse reactions experienced by patients taking Ilumya include upper respiratory infections, injection site reactions, and diarrhea. Other potential side effects include fungal infections, headache, and fatigue. Patients should contact their healthcare provider if they experience any unusual symptoms while taking Ilumya.
In conclusion, Ilumya is a medication used to treat moderate to severe plaque psoriasis in adults by selectively targeting IL-23 to reduce inflammation and skin cell proliferation. It is administered by a healthcare provider as a subcutaneous injection every 12 weeks. Before taking Ilumya, patients should inform their healthcare provider of any medical conditions they have, medications they are taking, and whether they are pregnant or planning to become pregnant. Ilumya should not be used in patients with a history of hypersensitivity or clinically significant active infections. Side effects may include upper respiratory infections, injection site reactions, and diarrhea, among others. Patients should consult their healthcare provider if they experience any unusual symptoms while taking Ilumya.
Reviews
There are no reviews yet.